AnaptysBio, Inc.
ANAB
$20.70
$0.090.44%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 48.39% | 11.95% | -17.10% | 0.72% | -59.81% |
| Total Depreciation and Amortization | -0.50% | 0.68% | 1.36% | 2.02% | -0.33% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 134.86% | 127.54% | 51.10% | 22.49% | 7.62% |
| Change in Net Operating Assets | -2,488.45% | 112.54% | 168.65% | -191.51% | -144.97% |
| Cash from Operations | -94.10% | 72.34% | 16.08% | -51.63% | -221.47% |
| Capital Expenditure | 6.07% | 78.40% | 82.63% | 84.57% | -60.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -158.90% | 90.46% | 88.11% | -19.78% | 128.21% |
| Cash from Investing | -159.77% | 91.35% | 88.06% | -19.65% | 128.77% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 110.23% | 61,460.63% | 25.03% | -35.89% | -92.28% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 606.51% | -743.66% | 2,371.57% | -1,000.08% | -268.91% |
| Cash from Financing | 634.35% | 2,418.68% | 410.48% | 63.72% | -364.70% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -808.39% | 1,443.96% | 130.54% | -23.76% | -24.22% |